Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
14.87
+0.91 (6.52%)
At close: Aug 10, 2026, 4:00 PM EDT
14.90
+0.03 (0.20%)
Pre-market: Aug 11, 2026, 8:17 AM EDT
Summit Therapeutics Employees
Summit Therapeutics had 265 employees as of December 31, 2025. The number of employees increased by 106 or 66.67% compared to the previous year.
Employees
265
Change (1Y)
106
Growth (1Y)
66.67%
Revenue / Employee
n/a
Profits / Employee
-$3,230,525
Market Cap
11.86B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 265 | 106 | 66.67% |
| Dec 31, 2024 | 159 | 54 | 51.43% |
| Dec 31, 2023 | 105 | 28 | 36.36% |
| Dec 31, 2022 | 77 | -33 | -30.00% |
| Dec 31, 2021 | 110 | 29 | 35.80% |
| Dec 31, 2020 | 81 | 11 | 15.71% |
| Dec 31, 2019 | 70 | 9 | 14.75% |
| Dec 31, 2018 | 61 | -15 | -19.74% |
| Dec 31, 2017 | 76 | 36 | 90.00% |
| Dec 31, 2016 | 40 | 3 | 8.11% |
| Dec 31, 2015 | 37 | 14 | 60.87% |
| Dec 31, 2014 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 1,220 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
SMMT News
- 4 days ago - These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks - Barrons
- 4 days ago - Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty - GlobeNewsWire
- 6 days ago - Summit announces expansion of development program for ivonescimab - TheFly
- 6 days ago - Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business Wire
- 17 days ago - Summit Therapeutics price target lowered to $15 from $17 at Jefferies - TheFly
- 17 days ago - H.C. Wainwright keeps Neutral on Summit Therapeutics after Q2 report - TheFly
- 18 days ago - Summit Therapeutics price target lowered to $38 from $45 at Stifel - TheFly
- 18 days ago - Summit Therapeutics price target lowered to $38 from $40 at Guggenheim - TheFly